Rare Seizure Disorder Gets Its First Drug Approval
Ganaxolone (Ztalmy) won approval to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD), a rare genetic epilepsy, in patients ages 2 and older, the FDA announced. Ganaxolone is a neuroactive steroid that acts as a positive allosteric modulator of the GABAA receptor. The oral therapy is the first drug approved specifically for […]